Group 1 - The core viewpoint of the article highlights that funds focused on innovative pharmaceuticals have seen significant gains, with some funds increasing over 61% in the first half of the year [1] - The top-performing funds include several that are primarily invested in innovative drugs, with the highest return being 86.48% for the fund "汇添富音港优势精选A" [1] - Other notable funds in the top 16 also show strong performance, with returns ranging from 61.77% to 83.15% [1] Group 2 - The article suggests that innovative drugs can be pursued when the market declines, indicating a potential buying opportunity [2] - The "广发成长领航一年持有A" fund has a significant portion of its holdings in new consumer concepts, with major investments in companies like 泡泡玛特 and 老铺黄金 [3] - The fund manager 吴远怡 has demonstrated strong performance across various products, with most showing commendable returns [4] Group 3 - The historical performance of the "广发科技创新" fund shows a maximum drawdown of -53%, indicating high volatility [5] - Overall, the funds discussed are characterized by high volatility and significant drawdowns, making them more suitable for investors willing to buy during market dips [7] - The article emphasizes that these funds may not be suitable for low-risk investors due to their performance characteristics [7]

Core Insights - The A-share market in the first half of 2025 exhibited a distinct structural trend, with pharmaceutical and biotechnology-themed funds dominating performance rankings [1] - Over 120 funds were liquidated during this period, indicating significant market shifts [1] Performance Summary Top Performing Funds - The top ten stock funds saw significant returns, with the leading fund, Huaan Pharmaceutical Bio A, achieving a return of 66.44% [2] - Other notable performers included Jiashi Huron Selected A (60.26%) and Ping An Pharmaceutical Selected A (58.80%) [2] - The average return of the top ten funds was driven primarily by smaller, actively managed funds, highlighting their flexibility in capturing rapid market movements [5] Underperforming Funds - The worst-performing funds were led by Jianxin China Manufacturing 2025 A, which recorded a decline of 14.68% [4] - Other funds in the bottom tier included Huaxia Advantage Selected and Great Wall Quantitative Selected A, both with declines exceeding 12% [4] - The coal and photovoltaic sectors faced significant downward pressure, with several funds in these categories showing substantial losses [4] Sector Analysis Pharmaceutical and Biotechnology - The pharmaceutical and biotechnology sectors have seen a resurgence after a prolonged adjustment period, driven by improved valuations and supportive policies [5] - The global and domestic biotech investment climate is recovering, contributing to the strong performance of related funds [5] Coal and Photovoltaic Industries - The coal industry is experiencing a shift in supply-demand dynamics, leading to downward pressure on valuations due to economic restructuring and accelerated energy transitions [5] - The photovoltaic sector is facing intensified competition and concerns over overcapacity, impacting short-term profitability and stock performance [5] Market Outlook - The A-share market is expected to show a trend of gradual upward movement in the second half of 2025, supported by increased participation from public funds and favorable policies [6] - However, significant differentiation among sectors may lead to rebalancing pressures, particularly in pharmaceuticals and biotechnology [6] - Investors are advised to analyze macroeconomic trends and industry policies to identify opportunities amidst market volatility [6]

Core Insights - The performance of ordinary equity funds in the first half of 2025 shows significant differentiation, with pharmaceutical-themed funds demonstrating a comparative advantage in both returns and risk control [1][2] - The Calmar Ratio indicates a stark contrast in investor experience, with pharmaceutical funds dominating the top rankings [1][2] Performance of Pharmaceutical Funds - The top 10 pharmaceutical funds achieved an average return of 52.75%, with Huaan Pharmaceutical Biotechnology A leading at 65.03% [2] - These funds exhibited effective drawdown control, with maximum drawdowns ranging from -9.90% to -15.82%, outperforming the industry average [2] - Huaan Pharmaceutical Biotechnology A has a Calmar Ratio of 14.60, indicating a significant risk-return advantage, while Zhongyin Health A and Fuguo Pharmaceutical Innovation A also showed strong performance with Calmar Ratios of 13.38 and 11.08, respectively [2][4] Underperformance of Technology and Low-Carbon Funds - Funds focused on technology and low-carbon themes displayed a mismatch between returns and risks, characterized by low returns and high drawdowns [2][4] - The bottom 10 funds had an average return of only 3.04% with maximum drawdowns reaching -30.77% [2][3] Comparison of Fund Performance - The worst-performing fund, Invesco Great Wall Quality Growth A, had a Calmar Ratio of 0.22, with a maximum drawdown of -30.77% for a mere 3.21% return [3][4] - The average Calmar Ratio of the bottom three funds was 0.24, indicating significant risk control shortcomings [4] Defensive Characteristics of Pharmaceutical Sector - The defensive nature of the pharmaceutical sector, supported by essential consumption and policy backing, provides a natural buffer against market volatility [4] - High Calmar Ratio pharmaceutical funds tend to have smaller asset sizes (1-10 billion), allowing for more flexible adjustments, while larger funds like Invesco Great Wall Research Select A (31.77 billion) face strategic implementation constraints [4] Importance of Risk-Adjusted Metrics - The data from the first half of 2025 emphasizes that solely pursuing high returns may obscure potential risks [5] - Investors are advised to focus on risk-adjusted return metrics like the Calmar Ratio, particularly for funds with returns below 5% but drawdowns exceeding 20% [5]

Core Insights - The performance of actively managed equity funds in the first five months of 2025 shows a significant disparity, with the best-performing fund achieving a return of 69.30% and the worst losing over 37%, resulting in a nearly 108% difference between the top and bottom performers [1] - The average return for all 4,516 actively managed equity funds was 2.64%, with 190 funds exceeding a 20% return in the first two months [1] - The North Exchange 50 Index outperformed other indices, leading to strong performances from several North Exchange-themed funds and a rebound in pharmaceutical-themed funds due to the strong performance of the innovative drug sector [1] Fund Performance - The top two funds in terms of performance for the first five months of 2025 were the CITIC Securities North Exchange Selected Two-Year Open A, managed by Leng Wenpeng, with a return of 69.30%, and the Huaxia North Exchange Innovative Small and Medium Enterprises Selected Two-Year Open, managed by Gu Xinfeng, with a return of 67.38% [1][5] - Other notable funds include Changcheng Pharmaceutical Industry Selected A and Guangfa Growth Navigation One-Year Holding A, both exceeding 60% returns [3] Sector Analysis - The innovative drug sector has seen a significant increase in market costs since 2022, with a notable second wave of cost increases occurring after the Lunar New Year [4] - The analysis suggests that the second wave of cost increases in the innovative drug sector may present greater potential for returns compared to the first wave, driven by a combination of policy, capital, and industry dynamics [4]